私たちは基礎研究をベースとする、技術開発型のベンチャー企業です。
私たちは製薬企業において、CAR-T 細胞※をはじめとする再生医療等製品の研究・開発経験があります。
私たちは「製薬会社品質の細胞」を目指して、細胞の長期凍結保存技術に特化した研究を継続して行います。
私たちは主に日本と東アジア地域における操業を目指しています。
私たちは高品質の細胞を提供することにより、日本の医療および、日本の再生医療研究に貢献したいと考えています。
※CAR-T 細胞：Chimeric Antigen Receptor(キメラ抗原受容体) と呼ばれる、 抗体とT細胞活性化因子を融合させた分子を導入したT細胞。これまでに血液がんに対する3品目が再生医療等製品として承認を受けています。

We have experience in research and development of regenerative medicine products including CAR-T cells*1 in pharmaceutical company.
Pharmaceutical companies manufacture pharmaceuticals and regenerative medicine products, always ensuring their quality, efficacy and safety in accordance with the Pharmaceutical Affairs Law*2 .
We have many years of experience in the pharmaceutical industry and provide “pharmaceutical-quality” long-term cell cryopreservation.
We also continue to conduct basic research specialized in cell cryopreservation technology. We hope to contribute to Japanese medicine and regenerative medicine research by providing high quality immune cells.
1 CAR-T cells: T cells in which a molecule called Chimeric Antigen Receptor, which is a fusion of an antibody and a T cell activating factor, is introduced. So far, three products have been approved as regenerative medicine products for hematological cancers.
2 Pharmaceutical Affairs Law: Law concerning the quality, efficacy and safety of pharmaceuticals, medical devices and other products.
The purpose of this law is to ensure the quality, efficacy and safety of pharmaceuticals, medical devices, cosmetics, and regenerative medicine products, and to improve health and hygiene.
* CAR-T cells: T cells that have been introduced with a molecule called a chimeric antigen receptor, which is a fusion of an antibody and a T cell activation factor. To date, three products for blood cancer have been approved as regenerative medicine products.